Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon J Cook

Showing results (11-20 of 100) with videos related to

Pageof 10
Sort By:
The Biochemical Journal|December 14, 2012
The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistanceMatthew J Sale, Simon J Cook
Autophagy|February 22, 2020
Macroautophagy is repressed during mitosis - seeing is believingRichard I Odle, Simon J Cook
The Biochemical Journal|February 18, 2014
The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G₁ cell-cycle arrest and not a direct effect on BIK protein stabilityMatthew J Sale, Simon J Cook
Frontiers in Cell and Developmental Biology|July 29, 2022
ERK5 Signalling and Resistance to ERK1/2 Pathway Therapeutics: The Path Less Travelled?Simon J Cook, Pamela A Lochhead
Biochemical Society Transactions|December 28, 2020
Inhibition of RAF dimers: it takes two to tangoFrazer A Cook, Simon J Cook
Cell Calcium|December 14, 2005
Recent advances in Ca(2+)-dependent Ras regulation and cell proliferationSimon J Cook, Peter J Lockyer
Cells|August 26, 2018
Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ InhibitorsJack A Prescott, Simon J Cook
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addictionMatthew J Sale, Kathryn Balmanno, Simon J Cook
Cellular Signalling|September 22, 2007
c-Cbl is not required for ERK1/2-dependent degradation of BimELCeri M Wiggins, Hamid Band, Simon J Cook
Pharmacology & Therapeutics|February 19, 2018
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathwayAndrew M Kidger, James Sipthorp, Simon J Cook
Pageof 10

Showing results (11-20 of 100) with videos related to

Sort By:
Pageof 10
The Biochemical Journal|December 14, 2012
The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistanceMatthew J Sale, Simon J Cook
Autophagy|February 22, 2020
Macroautophagy is repressed during mitosis - seeing is believingRichard I Odle, Simon J Cook
The Biochemical Journal|February 18, 2014
The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G₁ cell-cycle arrest and not a direct effect on BIK protein stabilityMatthew J Sale, Simon J Cook
Frontiers in Cell and Developmental Biology|July 29, 2022
ERK5 Signalling and Resistance to ERK1/2 Pathway Therapeutics: The Path Less Travelled?Simon J Cook, Pamela A Lochhead
Biochemical Society Transactions|December 28, 2020
Inhibition of RAF dimers: it takes two to tangoFrazer A Cook, Simon J Cook
Cell Calcium|December 14, 2005
Recent advances in Ca(2+)-dependent Ras regulation and cell proliferationSimon J Cook, Peter J Lockyer
Cells|August 26, 2018
Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ InhibitorsJack A Prescott, Simon J Cook
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addictionMatthew J Sale, Kathryn Balmanno, Simon J Cook
Cellular Signalling|September 22, 2007
c-Cbl is not required for ERK1/2-dependent degradation of BimELCeri M Wiggins, Hamid Band, Simon J Cook
Pharmacology & Therapeutics|February 19, 2018
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathwayAndrew M Kidger, James Sipthorp, Simon J Cook
Pageof 10